Guidance on substantial amendments to a clinical trial if the UK leaves the EU with no deal

U.K. MHRA Updates Information Pages in the Event of a No-Deal Brexit on August 6, 2019

This guidance covers significant amendments to a clinical trial including changes to the trial sponsor/legal representative, Investigational medicinal product (IMP) certification and importation and amendments to the Research Ethics Committee (REC).

Read more online
Copyright Widler & Schiemann AG 2015. All Rights Reserved. /